Upon confirmation, the court has declared that Occlutech is not infringing the Italian part of patent EP0808138 as alleged by St Jude-AGA Medical.

The favourable ruling affirms that Occlutech has its original technology that does not infringe the AGA-patent.

Occlutech CEO Tor Peters said they are convinced that when its technology is applied in cardiac occluders and many other minimally invasive implants it is a big step forward offering patients significant advantages.